← Russell 3000 cross-section

AMRX Amneal Pharmaceuticals, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$6.2bn
Revenue TTM
$3.1bn
Net income TTM
$157m
Free cash flow
$128m
Composite score
53.2
Sector rank
#948

Valuation

P / E
39.5
EV / EBITDA
EV / sales
2.8
FCF yield
2.06%
Earnings yield vs 10-yr
-2.20pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
5.0%
EBITDA margin
ROE
476.5%
ROIC
18.4%
Revenue growth
9.3%

Insider activity, last 90 days

Net open-market
$-7.22m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Cost of Goods Sold and Gross Profit Cost of goods sold increased 5.3% for the three months ended June 30, 2026 as compared to the prior year period. The increase in cost of goods sold was primarily due to increases in sales volume, plant and freight costs, and inventory obsolescence, partially offset by a reduction in amortization expense. Gross profit as a percentage of net revenue increased to 42.0% for the three months ended June 30, 2026 from 39.5% in the prior year period primarily due to lower amortization expense and operating leverage from higher sales volume. …Amneal Pharmaceuticals, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →